{"id":"midazolam-nasal-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation / drowsiness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL655","moleculeType":"Small molecule","molecularWeight":"325.77"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Midazolam binds to GABA-A receptors on neurons, potentiating the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx, hyperpolarizes neurons, and reduces neuronal excitability. The nasal spray formulation provides rapid onset of action suitable for acute sedation or anxiety management in clinical settings.","oneSentence":"Midazolam is a benzodiazepine that enhances inhibitory GABA neurotransmission in the central nervous system to produce sedation and anxiolysis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:21.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute seizure management or seizure cluster treatment"},{"name":"Pre-procedural sedation and anxiolysis"}]},"trialDetails":[{"nctId":"NCT06330584","phase":"PHASE2","title":"Administration of Intranasal Midazolam for Anxiety in Palliative Care","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-12-20","conditions":"Anxiety, Acute Anxiety, Palliative Care","enrollment":36},{"nctId":"NCT05383495","phase":"PHASE3","title":"Anxiolysis for Laceration Repair in Children","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2023-12-19","conditions":"Laceration of Skin, Distress, Emotional","enrollment":300},{"nctId":"NCT02820051","phase":"NA","title":"Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2014-02","conditions":"Conscious Sedation Failure During Procedure","enrollment":102},{"nctId":"NCT01744184","phase":"PHASE4","title":"A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy","status":"TERMINATED","sponsor":"The Royal Bournemouth Hospital","startDate":"2013-05","conditions":"Patients Requiring Diagnostic Gastroscopy With Sedation","enrollment":62},{"nctId":"NCT05670509","phase":"PHASE4","title":"Intranasal vs Buccal vs Intramuscular Midazolam for the Home and Emergency Treatment of Acute Seizures","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-01-19","conditions":"Convulsions","enrollment":305},{"nctId":"NCT05748795","phase":"","title":"Microbial Colonization in Lung Cancer Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-02-01","conditions":"Microbial Colonization","enrollment":103},{"nctId":"NCT04608734","phase":"PHASE2","title":"Buccal Versus Intranasal Route of Administration of Midazolam Spray in Behavior Management of Pre-School Patients","status":"COMPLETED","sponsor":"Nourhan M.Aly","startDate":"2015-06-10","conditions":"Dental Anxiety","enrollment":36},{"nctId":"NCT01390220","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters","status":"TERMINATED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2011-06","conditions":"Epilepsy","enrollment":292},{"nctId":"NCT02009306","phase":"PHASE4","title":"Nasal Fentanyl and Buccal Midazolam for Dying Patients","status":"COMPLETED","sponsor":"Gloucestershire Hospitals NHS Foundation Trust","startDate":"2017-01-23","conditions":"Terminal Cancer","enrollment":20},{"nctId":"NCT01316445","phase":"PHASE1","title":"Pharmacodynamics of Nasal and Buccal Midazolam Using EEG","status":"TERMINATED","sponsor":"Columbia University","startDate":"2011-07","conditions":"Epilepsy","enrollment":9},{"nctId":"NCT01288612","phase":"NA","title":"Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2011-02","conditions":"Barrett's Esophagus","enrollment":459}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"},{"count":1,"reaction":"ENCEPHALITIS"},{"count":1,"reaction":"GENERALISED TONIC-CLONIC SEIZURE"},{"count":1,"reaction":"HYPOAESTHESIA"},{"count":1,"reaction":"SEIZURE"},{"count":1,"reaction":"TREATMENT FAILURE"}],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Versed"],"phase":"phase_3","status":"active","brandName":"Midazolam Nasal Spray","genericName":"Midazolam Nasal Spray","companyName":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","companyId":"london-health-sciences-centre-research-institute-or-lawson-research-institute-of","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Midazolam is a benzodiazepine that enhances inhibitory GABA neurotransmission in the central nervous system to produce sedation and anxiolysis. Used for Acute seizure management or seizure cluster treatment, Pre-procedural sedation and anxiolysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}